Jane C. Weeks, MD, MSc (†); Hajime Uno, PhD; Nathan Taback, PhD; Gladys Ting, MS; Angel Cronin, MS; Thomas A. D'Amico, MD; Jonathan W. Friedberg, MD, MSc; Deborah Schrag, MD, MPH
Grant Support: Analytic work was supported by a grant from the National Cancer Institute to the Dana-Farber Cancer Institute (RC1CA146196). The National Comprehensive Cancer Network and 18 of its member cancer centers provided funding for abstraction of medical records and curation of the cancer outcomes database.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-2231.
Reproducible Research Statement: Study protocol: Not available. Statistical code: Available from Ms Cronin (e-mail, email@example.com). Data set: Interested investigators should contact Dr. Schrag (e-mail, firstname.lastname@example.org) for the requisite procedures to use the data.
Requests for Single Reprints: Deborah Schrag, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215; e-mail, email@example.com.
Current Author Addresses: Drs. Uno and Schrag, Ms. Ting, and Ms. Cronin: Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.
Dr. Taback: Department of Statistical Sciences, University of Toronto, 6th Floor, Sidney Smith Hall, 100 St. George Street, Toronto, Ontario M5S 3G3, Canada.
Dr. D'Amico: Duke University Medical Center, Box 3496, Duke South, White Zone, Room 3589, Durham, NC 27710.
Dr. Friedberg: James P. Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642.
Author Contributions: Conception and design: J.C. Weeks, N. Taback, G. Ting, T.A. D'Amico, J.W. Friedberg, D. Schrag.
Analysis and interpretation of the data: J.C. Weeks, N. Taback, G. Ting, A. Cronin, T.A. D'Amico, J.W. Friedberg, D. Schrag.
Drafting of the article: J.C. Weeks, H. Uno, N. Taback, G. Ting, A. Cronin, D. Schrag.
Critical revision of the article for important intellectual content: J.C. Weeks, T.A. D'Amico, J.W. Friedberg, D. Schrag.
Final approval of the article: H. Uno, N. Taback, A. Cronin, T.A. D'Amico, J.W. Friedberg, D. Schrag.
Provision of study materials or patients: J.C. Weeks, D. Schrag.
Statistical expertise: H. Uno, N. Taback, A. Cronin.
Obtaining of funding: J.C. Weeks, D. Schrag.
Administrative, technical, or logistic support: J.C. Weeks, G. Ting, D. Schrag.
Collection and assembly of data: J.C. Weeks, N. Taback, G. Ting, A. Cronin, D. Schrag.
Weeks JC, Uno H, Taback N, Ting G, Cronin A, D'Amico TA, et al. Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of Cancer: A Multi-institutional Cohort Study. Ann Intern Med. 2014;161:20-30. doi: 10.7326/M13-2231
Download citation file:
Published: Ann Intern Med. 2014;161(1):20-30.
When clinical practice is governed by evidence-based guidelines and there is consensus about their validity, practice variation should be minimal. For areas in which evidence gaps exist, greater variation is expected.
To systematically assess interinstitutional variation in management decisions for 4 common types of cancer.
Multi-institutional, observational cohort study of patients with cancer diagnosed between July 2006 through May 2011 and observed through 31 December 2011.
18 cancer centers participating in the formulation of treatment guidelines and systematic outcomes assessment through the National Comprehensive Cancer Network.
25 589 patients with incident breast cancer, colorectal cancer, lung cancer, or non-Hodgkin lymphoma.
Interinstitutional variation for 171 binary management decisions with varying levels of supporting evidence. For each decision, variation was characterized by the median absolute deviation of the center-specific proportions.
Interinstitutional variation was high (median absolute deviation >10%) for 35 of 171 (20%) oncology management decisions, including 9 of 22 (41%) decisions for non-Hodgkin lymphoma, 16 of 76 (21%) for breast cancer, 7 of 47 (15%) for lung cancer, and 3 of 26 (12%) for colorectal cancer. Forty-six percent of high-variance decisions involved imaging or diagnostic procedures and 37% involved choice of chemotherapy regimen. The evidence grade underpinning the 35 high-variance decisions was category 1 for 0%, 2A for 49%, and 2B/other for 51%.
Physician identifiers were unavailable, and results may not generalize outside of major cancer centers.
The substantial variation in institutional practice manifest among cancer centers reveals a lack of consensus about optimal management for common clinical scenarios. For clinicians, awareness of management decisions with high variation should prompt attention to patient preferences. For health systems, high variation can be used to prioritize comparative effectiveness research, patient–provider education, or pathway development.
National Cancer Institute and National Comprehensive Cancer Network.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only